Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
33:48
Primary biliary cholangitis: Appraising the changing therapeutic landscape
1:02:19
Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies
39:16
Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors
32:03
Vaccination strategies for pneumococcal disease: Update and perspectives on clinical need and impact
27:28
Precision targeting of MET in NSCLC: A multidisciplinary approach
31:53
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
38:00
Navigating the management of cholestatic pruritus in patients with PBC
33:26